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Acid-peptic disease is widely considered conquered or controlled, future
advances being refinements ofexisting treatments ratherthan radical new devel-
opments. Yet controversies remain and developments have yet to be made.
Duodenal ulcer: Daily maintenance treatment with the anti-secretory drugs, his-
tamine H2 receptor antagonists and proton pump blockers, controls duodenal
ulcereffectively, markedly reducing relapse rate at one year after treatment from
about 75 percent to 15 to 20 percent (and to about 10 percent on proton pump
blockers). In contrast, Helicobacter pylori eradication with a one to two week
course of treatment yields prolonged remission or cure. The consequent reduc-
tion in drug costs in individual patients, however, has been exceeded by increas-
ing community use on the more expensive proton pump blockers for the treat-
ment ofgastroesophageal reflux disease. The marked decline in elective surgery
since the introduction ofhistamine H2 receptor antagonists is commonly attrib-
uted to the power of these drugs. The fall, however, had started much earlier,
indicating that the decline is due to changing natural history. In contrast, com-
plication rates remain unaltered. An increasing proportion of newly diagnosed
duodenal ulcer patients are elderly, and more of them now present for the first
time with complications (in this center, about 40 percent), which consequently
cannot be forestalled. Thus, duodenal ulcer disease is likely to remain a problem
and in many will be a serious illness.
Gastroesophageal refluxdisease: The proton pump blockers have revolutionized
the treatment of gastroesophageal reflux disease. In clinical trials they have
proven markedly superior to the histamine H2 receptor antagonists in healing (at
eight weeks, 80 to 90 percent vs. 50 to 60 percent), symptom relief, prevention
of relapse on maintenance therapy and cost-effectiveness. However, several
issues remain. The prevalence of gastroesophageal reflux disease seems to be
rising and is now probably the commonest acid-peptic disease encountered in
the West. Most clinical trials comparing proton pump blockers vs. histamine H2
receptor antagonists have been done in patients with erosive esophagitis, where-
as the majority (50 to 60 percent) of patients with gastroesophageal reflux dis-
ease have milder, generally non-erosive, disease. The therapeutic gain ofproton
pump blockers diminishes in mild disease so may not be worth the higher drug
costs. This is an important area for investigation. The majority of patients with
erosive esophagitis relapse when treatment is stopped (about 75 percent at one
year). Relapse is markedly reduced (to 20 to 25 percent) by daily maintenance
treatment with proton pump blockers. Mild disease relapses less often, so long-
term therapy by intermittent treatment may prove acceptable and more cost-
effective than maintenance treatment. This strategy remains unexplored in trials.
The ideal profile ofan anti-secretory drug forintermittent treatment would com-
bine rapid onset of action (similar to histamine H2 receptor antagonists) with
powerful effect (as with proton pump blockers). The new class of drug, the
reversible proton pump blocker (e.g., BY841) approaches this requirement.
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INTRODUCTION
A common perception ofthe treatment ofacid-peptic disease is that it is a "dead sub-
ject"! There are no major issues left in therapy; with few exceptions newer treatments will
result at most only in marginal improvement, if not in efficacy and safety then in lower
cost. This viewpoint is understandable in the light of the spectacular advances in therapy
made with the development ofproton pump blockers (PPB)b and anti-Helicobacterpylori
treatment regimes.
While agreeing with much ofthis sentiment, I believe there are issues thatremain. The
purpose of this provocative and personal viewpoint is to draw attention to these matters.
Two areas have been selected: duodenal ulcer (DU) and gastroesophageal reflux disease
(GERD).
DUODENAL ULCER
Anti-secretory therapy: The story sofar
By the late 1980s, virtually all patients with DU could be successfully managed with
the histamine H2 receptor antagonists (H2RA). About one-third needed daily maintenance
treatment; these patients had frequently relapsing disease (arbitrarily three or more relaps-
es per year) or had suffered complications and often were elderly. The remaining two-
thirds, younger, fitter patients with milder, uncomplicated disease, could be managed
effectively with intermittent treatment at lower cost [1, 2].
Results from several studies on long-term maintenance treatmentwith low dose H2RA
confirmed their continued efficacy (for as long as the patients remained on treatment) [3-
7], the cumulative symptomatic relapse rate at one year offtherapy (or on placebo) being
50 to 80 percentcompared withonly five to 20percent on treatment. Mostrelapses on ther-
apy occur in the first two years; after five years the relapse rate in two studies was only 28
percent on 400 mg cimetidine nightly [4] and 39 percent on 150 mg ranitidine nightly [7].
However, in the longestfollow-up study so far, the relapse rate on 150 mg ranitidine night-
ly after nine years was a mere 13 percent [5]. Interruption of treatment is followed by
relapse (cumulatively, about 80 percent at five years) [8]; i.e., the disease is only con-
trolled, not cured, the benefit lasting only for as long as the patient continues treatment
("once he's stopped the drug, he starts where he left off" as a thoughtful editorial written
as far back as 1978 put it) [9]. However, from early days there were reports that mainte-
nance treatment lasting from one to five years may alter the natural history ofthe disease,
reflected by reduced relapse rate (compared with the pre-treatment pattern) when therapy
is stopped [10, 11].
Although symptomatic relapse rate was much reduced on maintenance treatment (see
above), periodic endoscopic checks in asymptomatic patients showed that silent but active
disease was common: for every patient with symptomatic recurrence, another would have
silent disease. Thus the treatment seemed more effective in preventing symptom recur-
rence than in controlling the disease process [4, 12]. H2RA maintenance therapy at a high-
er (healing) dose (e.g., 0.8 to 1 g cimetidine, 0.3 g ranitidine ) showed still further reduc-
tion in relapse rates in some studies [13] but not in others [14].
Maintenance therapy with PPB is effective, as would be predicted from the powerful
anti-secretory effect, although there are few studies comparing them against H2RA [15-
20]. One such study is our own investigation in very aggressive DU; cumulative relapse on
150 mg ranitidine at one year was 54 percentcompared with 19 percent on 10 mg omepra-
zole [21]. One reason for the dearth ofcomparative studies is that interest has shifted to H.
pylori treatment to achieve long-term control.
Prolonged maintenance therapy with H2RA has proven safe, and there is no reason
to believe the same will not apply to the PPB. The main drawback, however, is the
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inconvenience of daily (probably permanent) treatment and the expense. Examples of
approximate annual drug costs in the U.S. are: 400 mg cimetidine (generic) nightly,
$74.34; 150 mg ranitidine nightly, $251.01; 10 mg omeprazole daily, $389.02; 20 mg
omeprazole daily, $691.27.
Intermittent treatment aims at rapidly relieving symptoms and healing the ulcer in
eachrelapse without attempting to suppress the disease over the long term. Contrary to ear-
lier views, the majority ofpatients have fewer than two relapses per year, so each episode
can be treated with a short healing course of H2RA as and when needed [1]. Intermittent
treatment with omeprazole gave even better results than with cimetidine [22]. Though the
number of relapses over the next 12 months was similar in both treatment groups, as
expected, the remission period, i.e., the number ofdays not receiving treatment forrelapse,
was significantly longer in patients treated with omeprazole than with cimetidine (272 vs.
175 days; p < .01). Using a complex decision analysis and statistical model based on clin-
ical trial data comparing omeprazole and ranitidine, the likely outcome over a five-year
period was calculated. The predicted number ofrelapses was a median of four (range 0 to
9) in both groups. However, judged by other criteria, omeprazole had significant advan-
tages overranitidine: less likelihood ofrequiring a change to maintenance therapy for slow
healing or frequent relapses (15 percent vs. 26 percent) or ofelective surgery for unhealed
ulcer (1.6 percent vs. 7.2 percent), and lower direct costs, i.e., paid by the patients or soci-
ety (17,645 vs. 19,965 Swedish crowns, 1992 prices).
Finally, a variant ofintermittent treatment is "symptomatic self-care," the objective of
which aims to relieve symptoms only, the patiept titrating his/her own intake of tablets.
This strategy is suited for patients with mild disease [24] (i.e., patients with infrequent,
short-lived, easily controlled symptoms and without a history of ulcer complications).
ANTI-HELICOBACTER PYLORI THERAPY
This novel treatment exploded into the recently-stabilized world ofulcer control with
anti-secretory therapy and has rapidly and radically changed management. Successful bac-
terial eradication holds the glittering prospects of short-term treatment giving prolonged
remission and probably cure. This, in turn, would prevent ulcer complications. By remov-
ing the need for maintenance treatment, huge savings in drug costs would be made [25].
Have these come to pass?
The proven benefits ofH. pylori eradication
The long-term outcome: Cure: The early promise ofprolonged DU remission after H.
pylori eradication based on studies with one or two year follow-up [26, 27] has recently
been confirmed in two studies with longer follow-up: 5.1 to 7.6 years (mean: 6.5 years)
[28] and 1.4 to 10.9 years (mean: 4.7 years) [29]-. Recrudescence and re-infection rates are
low, probably between one to two percent per year [30, 31]. This minority is at risk ofre-
ulceration and needs further eradication therapy or maintenance treatment. For the major-
ity, it seems reasonable to assume further anti-secretory therapy for ulcer disease is no
longer required once the organism has been eradicated.
The abolition ofcomplications: Three studies have shown significant reduction ofre-
bleeding after successful H. pylori eradication in patients with peptic ulcer. In a small
study (n = 31), 29 percent re-bled on maintenance 300 mg ranitidine vs. none after H.
pylori eradication [32]; in another (n = 66), 38 percent bled again after failed H. pyloni
eradication but none after successful treatment [33]. In the largest study (n = 125), 12 per-
cent bled on maintenance 150 mg ranitidine or 20 mg omeprazole daily vs. only 2.3 per-
cent after eradication treatment [34]. Therefore, H. pylori eradication greatly reduces or
abolishes risk offurtherhemorrhage in patients known to have ulcer disease. Curiously, H.
pylori is less commonly present in patients with complicated ulcer than in the majority
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who present with dyspepsia and pain, so the benefits of successful treatment would be
expected only in those who harbor the organism [35-38].
The impact ofH. pylori treatment: the reality
Continuingpeptic ulcercomplications: Peptic ulcercomplications tend to occurmuch
more commonly in the elderly. The problem is that many such patients present for the first
time with complications, either having had symptoms earlier that were not identified as
ulcer-related or, equally common, never having had symptoms before. For example, 14
percent of young patients (age 34 or below ) seen here between 1979 to 1983 presented
with complications, 11 percent in 1984 to 1988 and 10 percent in 1989 to 1993. In con-
trast, complications were more common in patients aged 65 or more, the proportions pre-
senting in the three periods being 25 percent, 42 percent and 38 percent DU, respectively.
Half of the patients aged over 75 years presented for the first time with complications.
Thus, in patients known to have a DU, hemorrhage and perforation will be reduced by suc-
cessful anti-H. pylori treatment, but when these complications are the first manifestation
of the problem, they cannot be forestalled.
The development ofgastroesophageal reflux
The benefits of ulcer cure are to some extent offset by having to treat a proportion of
such patients with anti-secretory drugs again, this time for reflux. A recent large study of
203 DU patients, followed up for one to five years after successful H. pylori eradication,
confirmed very low DU recurrence (n = 5, of which four were associated with aspirin or
non-steroidal anti-inflammatory drugs [NSAID]). But, surprisingly, 10 percent of the
patients developed GERD, all with erosive changes [31].
A similar trend was seen in a large community program, where 706 patients were
treated. A subset of 163 was followed for a mean ofeight months (three months to two and
a half years). Intermittent heartburn, the cardinal symptom ofreflux disease, continued in
55 percent of those with persistent infection but also in 39 percent of patients with con-
firmed eradication. Furthermore, after anti-H. pylori therapy, 67 percent with persistent
infection had further anti-ulcer treatment from their doctor, as might be expected, but so
did 19 percent following successful therapy [39].
We have also observed in this centerthat GERD develops on a background ofDU. For
example, we have identified 1,364 patients with both DU and GERD (representing 12 per-
cent of 11,613 patients, of whom 5,049 had pure DU and 5200 GERD alone). In half, the
two conditions were found together atpresentation; and in three-quarters ofthe remainder,
GERD developed on follow-up after the patient had presented with DU, necessitating an
increase in the dose ofH2RA maintenance treatment or a change over to PPB maintenance
therapy. Thus, the DU may be cured but further anti-secretory therapy may still be needed
if GERD develops.
The impact ofanti-H. pylori therapy in the community
It is reasonably extrapolated from clinical trial results that curing DU in the commu-
nity will be followed by marked clinical and economic benefits, the latter through reduced
long-term drug costs. Indeed, various government bodies are encouraging this treatment
approach. The efficacy ofthis policy has been assessed recently, perhaps for the first time.
The results are not quite so encouraging but they do indicate what might be expected in
practice, in contrast to research studies.
A major program in Suffolk (UK), covering a population of 650,000, offered anti-H.
pylori treatment through general practitioners of patients with "proven" duodenal or gas-
tric ulcercurrently on long-term anti-secretory therapy. Such patients were identified from
their doctors' computer records. The serology for H. pylori was tested in 1,897 patients:
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duodenal ulcer, n = 923; gastric ulcer, n = 214; but also non-ulcer dyspepsia, n = 778.
Treatment (omeprazole, amoxycillin and metronidazole for one week) had a 92 percent
eradication efficacy rate in a subset examined by breath test. It was projected, therefore,
that around 1000 patients treated would have had their infection eradicated. Surveillance
of further anti-ulcer drug prescription showed a fall of 55 percent in patients with earlier
positive serology and by only three percent ofthose serologically negative. These savings,
however, were far exceeded by increased community expenditure on omeprazole used to
treat the increasing number of patients with GERD [40]. The savings on anti-secretory
treatment are not as large as one might have expected, and it is difficult to know why such
drugs were continued. Butthe surprise was the rising total drugbudget ofPPB forthe com-
munity as a whole.
A further problem is created because demand for diagnostic endoscopy exceeds sup-
ply. H. pylori serology testing is, therefore, being used in young dyspeptics (aged less than
45 years) to aid selection fortheprocedure. Those with negative serology are treated symp-
tomatically (anti-secretory drugs, etc.) while thosepositive (and/or are on NSAID) are gas-
troscoped and treated according to the findings [41-44]. A further development is growing
commercial pressure to treat serologically positive dyspeptics with anti-H. pylori therapy
without any endoscopy at all. As reflux disease becomes more recognized and ulcer dis-
ease less common, particularly in the young, the number of patients helped in the long-
term by anti-H. pylori therapy applied thus is likely to diminish and not bring about the
cost-benefits hoped for [45].
Antibiotic resistance
The increasing use of anti-H. pylori therapy raises concerns of anti-microbial resis-
tance. Such resistance is common in developing countries, reaching up to 90 percent; but
it is also fairly common in the West. For example, nitroimidazole resistance (either prima-
ry or secondary) in the European multi-center study ranged from seven to 49 percent
(mean 28 percent) [46]. In the recentlarge UK national study, the mean (range) proportion
ofstrains found resistant was to: metronidazole, 32 percent (11 to 68 percent); tinidazole,
28 percent (17 to 43 percent); clarithromycin, four percent (3 to 10 percent). Resistance to
amoxycillin was rare, less than one percent (0 to three percent) [47]. Other centers in the
West have reported similar patterns [48]. However, though resistance to nitroimidazoles
reduces theefficacy oftherapies containing metronidazole ortinidazole, on the whole such
treatment remains fairly effective [49].
Possibly ofgreater concern is the emergence ofresistance to the powerful new antibi-
otic, clarithromycin, which now is increasingly used in anti-H. pylori therapy. In this cen-
ter, for example, 10 of 70 patients whose H. pylori was not eradicated on pantoprazole +
tinidazole + clarithromycin, given for 10 days, had developed resistance to the macrolide,
having been sensitive at the start. Such resistance is thought to result from a mutation in
the ribosomal RNA ofthe 23S subunit. Thechange in antibiotic targetrenders the drug less
efficient and allows survival of mutant clones [50]. Fortunately the resistance is not
through plasmids, otherwise the risk of spread of this phenomenon among strains of H.
pylori would be greater.
Because oftremendous patient demand for anti-H. pylori treatment, fuelled in part by
mass media coverage, general practitioners are under pressure to treat. Increasingly,
patients are given treatment without any investigation, not even serology, in the belief "it
won't harm and may do good"! Such indiscriminate use may well make antibiotic resis-
tance a bigger problem.
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THE "CONQUEST" OF DUODENAL ULCER
Effective treatment or natural history?
With powerful anti-secretory treatment, and now anti-H. pylori therapy, one might
have expected DU to be conquered. Yet a good deal remains to be achieved. An example
is provided from the statistics from our own health region (Trent Regional Health
Authority, population 4.6 million). Elective surgery, a marker of severe ulcer disease, has
declined dramatically in recent years (as it has elsewhere) and supports this contention.Yet
this decline started long before the introduction ofmodem medical treatment; furthermore,
the rate ofdecline, year upon year, has not changed. This suggests changing natural histo-
ry plays a significant part in the altered pattern seen. In contrast, hemorrhage and perfora-
tion are unchanged, indeed rising in the over 65-year-old population despite a more than
three-fold increase in H2RA use [51]. Further evidence ofthe influence of natural history
can be seen in the prevalence of H2RA-refractory DU in our center (defined as failure to
heal within threemonths on H2RA given at standard dose or greaterdose). Here theH2RA,
principally cimetidine, was (and remains) the main anti-ulcer drug used. The incidence of
refractoriness was: 1976 to 1978, 127/397 (32 percent); 1979 to 1983, 406/1272 (32 per-
cent); 1984 to 1988, 200/1308 (15 percent); 1989 to 1993, 79/1120 (7 percent). These
changes precede the use of PPB in this center [52]. Thus, the decline ofDU is perhaps as
much due to a changing natural history as to powerful medical treatment.
COMMENTS
1. In the West, nature has reduced the number ofpatients with new DU. Those who
come to medical attention can now be swiftly treated medically and probably be cured.
However, a higher proportion of patients are now older. For many, the first sign of ulcer
disease is hemorrhage or perforation: these complications cannot be prevented (though
treatment of the underlying disease should be able to reduce or prevent recurrence).
2. To abolish peptic ulcer requires treatment not only of proven cases but also of
those at risk, namely, people infected with H. pylori, most of whom are asymptomatic.
Modern anti-H. pylori treatment is effective (one-week therapy: greater than 90 percent
eradication) but still carries side-effects sufficiently often to make it unattractive for mass
treatment of the asymptomatic as part of a "public health campaign." Equally important,
the present treatment, though affordable in the West, is beyond the financial means of
many in developing countries where ulcer disease is rife.
3. Vaccination may be the future approach. Experimental work shows it prevents
infection and, intriguingly, can cure it [53-55]. However, it will be some years before this
strategy is available for mass use. Despite spectacular advances in treatment, duodenal
ulcer and its complications will be with us for a long time to come.
GASTROESOPHAGEAL REFLUX DISEASE
The superiority ofPPB overH2RA
The achievements: PPB is markedly superior to H2RA in treating erosive esophagitis.
After eight weeks of therapy, the approximate healing rates in clinical trials are: PPB in
standard doses (20 mg omeprazole, 30 mg lansoprazole, 40 mg pantoprazole), 80 to 90
percent; H2RA (300 mg ranitidine, 1.6 g cimetidine), 50 to 60 percent [56, 57]. Symptom
reliefis more rapid, the proportions free ofheartburn at four weeks being about 75 to 80
percent on PPB compared with 45 to 50 percent on H2RA. After healing, maintenance
therapy with PPB gives markedly better results than withH2RA. Relapse at one year, after
300 mg ranitidine, ranges from 55 to 79 percent whereas on 20 mg omeprazole it is only
12 to 28 percent. Ten mg omeprazole is less effective than the higher dose but superior to
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ranitidine, with relapse rates of37 to 50 percent. A similar pattern is seen with 30 mg lan-
soprazole (relapse, 10 to 20 percent) and 15 mg lansoprazole (13 to 31 percent) [58-66].
Treatment with PPB is also more cost-effective. Using a model derived from clinical tri-
als and common clinical practice, the drug cost fortreating 100 patients over a year (cov-
ering healing, relapse, re-healing and maintenance therapy) was $62,272.50 forranitidine
and $47,125 for omeprazole, a reduction of32 percent [67]. As lansoprazole is a little less
expensive than omeprazole, the saving would be even greater. Thus, on grounds ofeffica-
cy (in healing, relieving symptoms and preventing relapse by maintenance therapy) and
cost-effectiveness, the case for routine use ofPPB in GERD is overwhelming. But is this
the full story? I suggest not. Some ofthe issues are discussed below.
THE TREATMENT OF GERD: AREAS TO BE EXPLORED
Symptomatic gastroesophageal reflux inpatients with normal endoscopy
Virtually every trial comparing the PPB against H2RA has been done in patients with
erosive esophagitis. This is understandable, for healing of the breached mucosa is clearly
recognizable and healing rates, therefore, measurable. In patients with symptomatic gas-
troesophageal reflux but with normal mucosa, however, symptom improvement is the only
quantifiable parameter, and being subjective is less accurate. Yet in reflux disease about
halfthe patients investigated in hospital have normal endoscopy and the proportion in gen-
eral practice is higher still [68-70]. For example, in this center only 42 percent of 2,786
patients seen between 1989 to 1993 had erosive changes.
Itremains to be proven ifthemargin ofsuperiQrity ofPPB overH2RA in suchpatients
is great enough to make it cost-effective. Results from an important study ofpatients with
erosive esophagitis give some indication what might be expected in less severe disease. In
this investigation omeprazole proved superior to ranitidine, as expected. The cost-benefit
ofomeprazole was greatest in patients with severe erosive changes, when symptoms were
very troublesome and index of life-satisfaction low. There was little difference, however,
in mild disease; indeed, when the index oflife-satisfaction was only slightly reduced, ran-
itidine proved marginally more cost-effective [71].
Treatmentofmildgastroesophageal reflux: A recent large study ofpatients with reflux
seen in family practice showed ranitidine was significantly superior to placebo for reliev-
ing symptoms and improving the quality of life [72]. Similarly, omeprazole was clearly
superior to placebo in the two studies done so far on the treatment ofsymptomatic reflux
in patients with normal endoscopy [73,74]. Three interesting additional findings emerged
from these studies. First, the co-existence ofirritable bowel syndrome was associated with
a poorer outcome [73]. Second, the diagnostic accuracy of gastroesophageal reflux when
judged against the gold standard of esophageal pHmetry varied from 22 to 85 percent
across the 16 participating centers [74]. Third, the greater the reflux, the greater was the
benefit produced by omeprazole [74]. Irritable bowel syndrome is commonly present in
patients with symptomatic gastroesophageal reflux but with normal endoscopy, and reflux
itselfmay be mild despite symptoms.Although the advantage ofPPB over placebo in such
patients is clear, it cannot necessarily be assumed it will be superior over the H2RA to an
extent as to make it cost-effective.
This area wasinvestigated recently in alarge study of994patients with heartburn seen
in general practice, one-third ofwhom had mild erosive changes. Twenty mg omeprazole,
10 mg omeprazole and 150 mg ranitidine twice daily relieved heartburn in 61 percent, 49
percent and 40 percent of patients, respectively; the cost per treatment success being
$87.00, $61.50 and $97.50, respectively. In the subgroup with erosive esophagitis, symp-
tom relief was still higher on 20 mg omeprazole, 79 percent compared with 48 percent on
the 10 mg dose and 33 percent on ranitidine; the corresponding cost of treatment success
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was $67.50, $63.00 and $118.50, respectively. This important study, probably the first of
its type, clearly shows that PPB is superior [75].
The natural history ofGERD: Based on clinical trials, relapse off therapy is general-
ly thought to occur in 50 to 80 percent ofpatients with erosive esophagitis within six to 12
months. However, this is not always the case. For example, in a major study of 1030
patients with erosive disease healed on omeprazole or H2RA, the relapse rate at six months
was only 25 percent [76]. A similar low relapse rate on placebo was observed in some of
the early maintenance studies investigating H2RA [77].
A recent report described the outcome of a large group ofreflux patients followed for
up to six years [78]. At the end ofthe follow-up, one-third ofpatients were asymptomatic
or controlled their symptoms adequately with occasional doses (22 percent) or courses (16
percent) of antacids. A further 17 percent needed antacids frequently, 19 percent were on
maintenance H2RA (including eight percent on high dose) and 26 percent had had surgery.
This study was started before PPB were available, and today the proportions on acid sup-
pression would be different. But, importantly, the study emphasizes the benign nature of
reflux in many patients, reflected by the fact that one-third controlled their symptoms with
infrequent use of antacids alone.
The aim oftreatment
There is no "medical cure" of reflux; the disease is only controlled. There is no evi-
dence that short-term vigorous treatment early on (e.g., with high-dose PPB) in patients
with mild disease improves long-term outcome. Consequently, except in clinical trials,
symtom relief is the principal aim of treatment In clinical practice few have repeat
endoscopy to confirm healing, unless disease was severe to start with.
Alternative therapeutic approaches
Intermittent treatment: Long-term treatment can be tailored according to the severity
of symptoms. Theoretically, patients with mild, infrequent relapses could be treated for
short periods and therapy repeated as needed, i.e., intermittent treatment (as has been used
in duodenal ulcer). Such an approach is commonly used in general practice, but no study
has reported on the outcome ofsuch a policy. However, ranitidine given intermittently has
recently proved almost as effective as when given by daily maintenance therapy (unpub-
lished data: personal communication). Intuitively, younger, fitter patients with mild inter-
mittent symptoms and with normal endoscopy, or at most with mild erosive changes,
would be selected for such an approach.
Is there still a placefor the H2RA? H2RA is more effective than placebo in healing
erosive esophagitis (60 percent vs. 30 percent at six to eight weeks) [79] (although not
nearly so dramatic as in duodenal ulcer disease, when greater than 80 percent healing
would be expected). Low-dose maintenance therapy is generally ineffective in preventing
relapse [56]. These observations, together with the superior results achieved with proton
pump blockers, created the general impression that H2RA has little or no place in the man-
agement ofGERD [80]. I believe this conclusion premature for the following reasons:
1. Personal experience: Between 1976 to 1988, 1200 patients in this center were
treated satisfactorily with H2RA, principally 1.6 to 2 g cimetidine (or 0.45 to 0.6 g raniti-
dine ), both in the short- and long-term. The majority, 85 percent, continued with little or
no symptom recurrence. In halfofthe remaining 15 percent, control was achieved by dou-
bling the dose. The remainder needed omeprazole. Today, many more people are treated
with PPB, but in almost two-thirds, H2RA suffices.
2. H2RA: rapid response: Many patients with reflux have symptoms at specific
times, for example, after their main meal. A moderate degree of acid suppression for a
short period with appropriately-timed treatment suffices. This is feasible with the
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H2RA, particularly the effervescent preparations [81-84], whereas the PPB lacks such
flexibility.
3. Cost-benefit: PPB will remain expensive for several years more, whereas the price
of H2RA has fallen markedly. Earlier cost-benefit studies therefore need reassessing. In
groups where the clinical advantage ofPPB is slight, it may now be more cost-effective to
use H2RA.
The rising prevalence ofGERD
It is common experience that reflux disease is now seen more frequently. Figure 1
shows the number of new patients seen in this center each year from 1976 to 1994 with
GERD (erosive and non-erosive disease), duodenal and gastric ulcer. The rising numbers
of patients with GERD is striking. As this was not a formal epidemiological study, con-
clusions on changing prevalence have to be tentative and limited. The annual number of
endoscopies since 1980 has not changed, so the rise cannot be entirely explained by
increasing use of diagnostic methods. Greater awareness of GERD, particularly of non-
erosive disease, presumably contributes. However, it is difficult to avoid thepossibility that
at least a part ofthe rising numbers results from a true increase in prevalence.
The "middle ground"
Is there a needfora new molecule? PPB will dominate the treatment ofmore severe
disease; antacid-alginate preparations are perhaps all that are needed in very mild cases,
and H2RA, and prokinetics suffice for those with troublesome symptoms. It is the large
group in between these two ends where treatment strategies need to be re-examined, and
the number of patients in this group is steadily increasing as reflux disease is more fre-
quently diagnosed. Such patients have moderately troublesome symptoms that recur in
short relapses followed by longer remissions. The irreversible PPB (omeprazole, lanso-
prazole, pantoprazole) takes three to four days to reach peak effect, so is more suited for
patients who need continuous long-term treatment (although recent evidence suggests
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lansoprazole may have a reasonable "first-day" effect and suppresses acid more quickly
than omeprazole) [85]. H2RA acts rapidly, particularly the effervescent preparations, but
do not sustain pH above 4 for long enough [81-84].
A new type ofdrug, therefore, needs to be considered: Ideally it should: raise the pH
above 4 rapidly; sustain this pH level for eight to 10 hours, thus requiring no more than
twice daily dosing (and once daily would suffice ifsymptoms occur only at certain times);
have no attenuation ofeffect in the short-term (say up to four weeks ofdaily use). The new
generation of reversible-PPB approaches this [86]. If the early encouraging results from
pharmacological studies are confirmed, these drugs would allow treatment to be tailored
more accurately to individual patients' needs. For example, patients with symptoms con-
fined tothedaytime need take only amorning dose; and ifrelapses areshort-lived, thedrug
would be suitable for intermittent therapy. Ifmore frequent andlongerperiods oftreatment
become necessary, the patients would have selected themselves for long-term treatment
with irreversible PPB.
Preliminary anti-H. pylori therapy?
A recent report cautioned on the development of corpus gastritis within eight weeks
ofomeprazole treatment in patients with H. pylori despite unchanged degree ofcoloniza-
tion. This phenomenon was absent in patients who did not harbor the organism. As PPB is
often needed for long periods, the investigators recommended eradicating H. pylori first
[87]. If this report is confirmed, a new consideration enters the treatment ofGERD.
CONCLUSIONS
1. In severe disease, or where relapse is rapid and often, treatment with irreversible
PPB is needed, permanent in most. Surgery is the alternative but only in some patients; the
proportion may rise if good results from laparoscopic fundoplication become more wide-
ly available.
2. H2RA is under-valued. It is useful in patients with mild symptoms.
3. Intermittent treatment as a strategy needs to be investigated. Theoretically it
seems suitable for patients with mild or moderately troublesome disease with infrequent
relapses.
4. There is a place for a new molecule specifically for patients needing intermittent
treatment for whom H2RA is not powerful enough and the irreversible PPB excessive. The
reversible PPB may prove to have the appropriate properties.
5. There is a suggestion eradicating H. pylori first may prevent or reduce the devel-
opment ofcorpus gastritis in patients needing long-term PPB.
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